SCHEMBL802064

SCHEMBL802064

Cc1ccccc1-c1cc(Nc2n[nH]c3ccccc23)cc(C2CCCCC2)n1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 1/20 0.42
GSK3B P49841 1/20 0.42
FADS1 O60427 2/20 0.41
TRPA1 O75762 1/20 0.41
GRM4 Q14833 5/20 0.40
ADORA3 P0DMS8 4/20 0.37
ADORA2A P29274 2/20 0.37
ADORA1 P30542 2/20 0.37
ADRA2A P08913 2/20 0.37
PDE5A O76074 1/20 0.36
CYP1A2 P05177 1/20 0.36
SMYD2 Q9NRG4 1/20 0.35
TMEM97 Q5BJF2 3/20 0.35
SIGMAR1 Q99720 2/20 0.35
ITK Q08881 1/20 0.35
DRD3 P35462 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL802068 0.91 FADS1 (0.41) FADS1TRPA1GRM4ADRA2ACYP1A2
SCHEMBL801685 0.89 GSK3B (0.47) GSK3AGSK3BFADS1TRPA1CYP1A2
SCHEMBL802710 0.88 GSK3A (0.42) GSK3AGSK3BFADS1TRPA1GRM4
SCHEMBL12619882 0.85 USP1 (0.43) GSK3AGSK3BFADS1TRPA1GRM4
SCHEMBL802027 0.83 FADS1 (0.46) GSK3AGSK3BFADS1TRPA1GRM4
SCHEMBL802326 0.82 FADS1 (0.48) FADS1TRPA1GRM4ADRA2ACYP1A2
SCHEMBL802067 0.80 AURKA (0.38) GSK3AGSK3BCYP1A2SMYD2ITK
SCHEMBL802321 0.78 GSK3A (0.56) GSK3AGSK3BFADS1ADORA1SMYD2
SCHEMBL13055204 0.77 FADS1 (0.36) GSK3AGSK3BFADS1TRPA1GRM4
SCHEMBL12619886 0.77 CYP1A2 (0.43) FADS1TRPA1GRM4ADRA2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 GSK3A 2/4885GSK3B 1/4885FADS1 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.